Dr. Reddy’s Laboratories (RDY) signed a non-binding Memorandum of Understanding (MoU) with Kainomyx, Inc. to develop and commercialize affordable anti-malarial drug in the United States, EU and low and middle-income countries. Kainomyx is a U.S.-based company that utilizes its proprietary platform to develop candidates with a novel mechanism of action.  Per Dr. Reddy’s, the MoU is subject to the signing of a definitive agreement.There is a significant unmet medical need in the treatment of malaria and other ...